Benitec Biopharma Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 338.2K | $3.60M | 0.00% | Added+38.0% | 2026-03-31 |
| FidelityFMR | fundamental | 1.7K | $17.61K | 0.00% | Added+26.2% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-09-22upcoming | -0.28 | — | — |
| 2026-05-14 | -0.28 | -0.24 | +12.73% |
| 2026-02-12 | -0.23 | -0.26 | -15.04% |
| 2025-11-14 | -0.36 | -0.22 | +38.20% |
| 2025-09-22 | -0.31 | -0.42 | -34.25% |
| 2025-05-14 | -0.35 | -0.24 | +31.10% |
| 2025-02-14 | -0.78 | -0.33 | +57.46% |
| 2024-11-14 | -0.55 | -0.48 | +12.73% |
| 2024-05-13 | -0.78 | -1.64 | -110.26% |
| 2024-02-13 | -0.39 | -2.64 | -576.92% |
| 2023-11-13 | -0.51 | -2.76 | -441.18% |
| 2023-05-15 | -3.40 | -2.72 | +20.00% |
| 2023-02-13 | -1.87 | -3.40 | -81.82% |
| 2022-11-10 | -4.25 | -7.99 | -88.00% |
| 2022-09-02 | -4.76 | -10.54 | -121.43% |
| 2022-05-16 | -7.48 | -6.80 | +9.09% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BNTC | -3.26% | +10.52% | -14.18% | -24.74% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -6.23% | +15.15% | -10.74% | -37.43% |